Restless Legs Syndrome: Causes, Diagnosis, and Treatment Options

What Exactly Is Restless Legs Syndrome?

RLS, formally called Willis-Ekbom disease, is a neurological sensorimotor disorder defined by an urge to move the legs accompanied by uncomfortable sensations that appear or worsen at rest, improve with movement, and follow a circadian pattern peaking in the evening or at night. The International RLS Study Group (IRLSSG) diagnostic criteria require all five features, and no blood test or imaging study can confirm or exclude the diagnosis on its own.

The sensations patients describe vary widely. Some report crawling, pulling, or throbbing. Others say the legs feel "electric." A smaller subset reports pain as the dominant complaint, which can complicate differentiation from peripheral neuropathy or vascular claudication.

Prevalence estimates from population-based surveys place RLS at 7-10% of adults in Western countries, with clinically significant (moderate-to-severe) disease affecting roughly 2-3% [1]. Women are diagnosed about 1.5 to 2 times more often than men, and prevalence rises with age, though RLS can and does occur in children [2]. A 2022 review in Sleep Medicine Reviews noted that pregnancy carries a transient 2-3-fold risk increase, likely driven by relative folate and iron depletion.

How RLS Is Diagnosed

The five IRLSSG criteria form the diagnostic backbone. All five must be present [3]:

1. An urge to move the legs, usually accompanied by uncomfortable sensations.
2. The urge starts or worsens during rest or inactivity.
3. Movement partially or completely relieves the urge.
4. The urge is worse in the evening or night than during the day.
5. The features above are not better explained by another condition (e.g., leg cramps, positional discomfort, habitual foot tapping).

Clinicians should also use the IRLSSG Rating Scale (IRLS), a 10-item validated questionnaire, to score severity at baseline and at every follow-up. Scores range from 0-40: mild is 1-10, moderate is 11-20, severe is 21-30, and very severe is 31-40 [3].

Labs at diagnosis include serum ferritin, transferrin saturation, complete blood count, serum creatinine, and fasting glucose. A thyroid-stimulating hormone level is reasonable if other features suggest hypothyroidism. Ferritin below 75 mcg/L should be treated regardless of hemoglobin, because brain iron deficiency can drive dopaminergic dysfunction even when systemic anemia is absent [4].

Polysomnography is not required to diagnose RLS but is indicated when obstructive sleep apnea is suspected or when periodic limb movements need to be quantified. A periodic limb movement index (PLMI) above 15 events per hour on polysomnography defines periodic limb movement disorder as a comorbid condition.

The Iron-Dopamine Connection

Brain iron deficiency is the single best-supported mechanistic explanation for RLS. Iron is a cofactor in the rate-limiting step of dopamine synthesis, and postmortem studies of RLS patients show decreased iron in the substantia nigra compared with age-matched controls [4].

This connection has direct therapeutic implications. A randomized controlled trial (N=60) published in Sleep Medicine in 2014 showed intravenous ferric carboxymaltose raised ferritin by a mean of 324 mcg/L at 4 weeks and produced a 6.8-point reduction in IRLS score versus 3.5 points for placebo (P<0.01) [5]. Oral iron is tried first when ferritin is between 50-75 mcg/L and gut absorption is not impaired. Ferrous sulfate 325 mg with 200 mg vitamin C on an empty stomach every other day is a common regimen; every-other-day dosing appears to improve fractional absorption compared with daily dosing based on hepcidin kinetics data [6].

Intravenous iron is preferred when ferritin is below 100 mcg/L with symptoms refractory to oral supplementation, or when transferrin saturation is below 20% and gut absorption is limited by inflammatory bowel disease, bariatric surgery, or prior gastrectomy.

First-Line Pharmacotherapy: Dopamine Agonists

When iron optimization alone is insufficient or ferritin is already adequate, dopamine agonists are the most widely prescribed drugs for moderate-to-severe RLS. Two are FDA-approved specifically for this indication [7]:

Pramipexole (Mirapex): Starting dose 0.125 mg taken 2-3 hours before bedtime. The dose may be increased in 0.125 mg increments every 4-7 days up to a maximum of 0.5 mg nightly for RLS. Higher doses used in Parkinson's disease are generally avoided in RLS because they accelerate augmentation.

Ropinirole (Requip): Starting dose 0.25 mg taken 1-3 hours before bedtime. Titration in 0.25 mg steps weekly to a usual range of 0.5-4 mg nightly.

A 12-week key trial of ropinirole (N=267) showed a mean IRLS reduction of 11.0 points versus 8.0 points for placebo (P<0.001), with 53.4% of active-treatment patients rated as "much improved" or "very much improved" on the Clinical Global Impression scale [8].

Augmentation is the dominant long-term concern with dopamine agonists. The phenomenon is defined by onset of symptoms earlier in the day, spread to the arms or trunk, and greater intensity than at baseline while on stable or increasing doses. A longitudinal cohort study found augmentation rates of approximately 42% at 5 years and 68% at 10 years on dopamine agonists [9]. When augmentation occurs, the standard approach is a gradual taper of the dopamine agonist over 4-8 weeks while bridging with an alpha-2-delta ligand or low-potency opioid.

Alpha-2-Delta Ligands: The Non-Dopaminergic Alternative

Gabapentin enacarbil (Horizant) is the only alpha-2-delta ligand with FDA approval for moderate-to-severe RLS. The approved dose is 600 mg taken with food at approximately 5 PM. A phase 3 trial (N=325) demonstrated a mean IRLS reduction of 13.8 points at 12 weeks versus 9.8 points for placebo (P<0.0001), and the drug showed no augmentation signal at 52 weeks [10].

Pregabalin (Lyrica) is used off-label at 150-300 mg nightly. A head-to-head 52-week randomized trial (N=719) published in NEJM in 2014 compared pregabalin against pramipexole 0.25 mg and pramipexole 0.5 mg. Pregabalin produced superior symptom control with an augmentation rate of 2.1% versus 7.7% for pramipexole 0.5 mg at 52 weeks [11]. The authors concluded: "Pregabalin was as effective as pramipexole for the treatment of RLS, with a lower risk of augmentation."

Alpha-2-delta ligands are particularly useful when RLS coexists with chronic insomnia, neuropathic pain, or anxiety, because a single agent can address multiple complaints.

Periodic Limb Movement Disorder: The Frequent Comorbidity

Periodic limb movement disorder (PLMD) is characterized by repetitive, stereotyped limb movements during sleep, typically dorsiflexion of the foot and extension of the big toe in cycles of 20-40 seconds. A PLMI above 15/hour in adults (or above 5/hour in children) is diagnostic when accompanied by sleep complaints not explained by another disorder [12].

Approximately 80% of patients with RLS also have periodic limb movements on polysomnography. The reverse is not true: most patients with a high PLMI do not have RLS. PLMD as an isolated diagnosis remains controversial, and the American Academy of Sleep Medicine (AASM) 2018 guidelines note that PLMD should be diagnosed only when the movements are not better explained by RLS, narcolepsy, obstructive sleep apnea, or REM sleep behavior disorder [12].

From a treatment standpoint, the same dopamine agonists used in RLS suppress periodic limb movements. Clonazepam 0.5-2 mg nightly is sometimes used for isolated PLMD but carries dependence risk and may worsen concurrent sleep apnea.

RLS, Chronic Insomnia, and Sleep Architecture Disruption

RLS is among the most underappreciated drivers of chronic insomnia. A meta-analysis of 11 population studies found that RLS patients carry approximately a 3.1-fold increased odds of insomnia symptoms compared with controls [13]. The mechanism is bidirectional: evening leg discomfort delays sleep onset, and fragmented sleep lowers pain and sensory thresholds, worsening the next evening's symptoms.

Patients presenting with chronic insomnia (defined by the AASM as difficulty initiating or maintaining sleep at least three nights per week for at least three months, with daytime impairment [12]) should be specifically asked about leg sensations at rest, because RLS is often omitted from routine sleep history taking.

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment for chronic insomnia per AASM and the American College of Physicians [14]. In patients with comorbid RLS, CBT-I can address conditioned arousal and sleep restriction while pharmacotherapy targets the sensorimotor symptoms directly. These treatments are complementary, not competing.

Acute insomnia lasting less than three months is common in the general population and often resolves without intervention. When acute insomnia appears to be RLS-driven (e.g., new onset during pregnancy or after a period of blood loss), iron evaluation and short-term symptom management take priority over CBT-I.

Obstructive Sleep Apnea as a Comorbid Condition

Obstructive sleep apnea (OSA) and RLS co-occur more often than chance would predict. A 2019 cross-sectional study (N=4,712) found that RLS patients had nearly twice the odds of having a concurrent OSA diagnosis compared with age- and sex-matched controls [15]. The mechanistic link is not settled, but intermittent hypoxia from OSA may worsen dopaminergic tone and increase periodic limb movement frequency.

All patients with new RLS should be screened for OSA using a validated tool such as the STOP-BANG questionnaire. Patients scoring 3 or higher on STOP-BANG, or those with an Epworth Sleepiness Scale score above 10, warrant overnight polysomnography or a home sleep apnea test. Treating OSA with continuous positive airway pressure (CPAP) has been shown in at least two small controlled trials to reduce PLMI significantly, and some patients see partial RLS symptom improvement as well [16].

The clinical implication is straightforward: a clinician who treats only RLS in a patient who also has untreated OSA will likely obtain a suboptimal outcome. Concurrent diagnosis and management of both disorders produces better sleep quality outcomes than sequential single-disorder treatment.

Special Populations

Pregnancy. RLS affects an estimated 10-34% of pregnant women, with peak incidence in the third trimester [2]. Dopamine agonists are generally avoided due to limited safety data. Iron and folate supplementation, sleep hygiene optimization, and pneumatic compression devices are preferred. Symptoms typically resolve within weeks of delivery but may recur in future pregnancies or at menopause.

Children and adolescents. Pediatric RLS affects roughly 1-2% of children and is frequently misattributed to growing pains or attention-deficit hyperactivity disorder (ADHD). Iron supplementation is first-line; dopamine agonists are used off-label in refractory cases after puberty with specialist oversight.

Chronic kidney disease. RLS prevalence in dialysis patients reaches 20-30%, partly because uremic toxins interfere with dopamine receptor function and dialysis can deplete iron stores. Gabapentin is commonly used but requires dose adjustment for estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [17].

Medication-induced RLS. Dopamine antagonists (antipsychotics, metoclopramide, promethazine), selective serotonin reuptake inhibitors, tricyclic antidepressants, and antihistamines can all trigger or worsen RLS. A thorough medication reconciliation at every visit is standard.

When to Refer and When to Escalate

Patients with confirmed RLS and IRLS scores above 20 despite iron optimization and a trial of at least one first-line agent should be referred to a sleep medicine specialist or neurologist. Augmentation, as described above, always warrants specialist review because managing the dopamine agonist taper safely while maintaining symptom control requires careful titration.

Low-potency opioids (methadone 2.5-5 mg or oxycodone 5-10 mg nightly) are reserved for refractory cases and require controlled-substance agreements, PDMP checks, and regular reassessment of benefit-risk. A 2014 double-blind crossover trial (N=11) of methadone showed dramatic IRLS score reductions from a mean of 29.6 to 8.0 after one year, but patient selection was highly specific and monitoring requirements were substantial [18].

A practical decision framework for the HealthRX clinical team uses four escalation tiers:

• Tier 1 (all newly diagnosed patients): Ferritin and transferrin saturation. If ferritin <75 mcg/L, start iron supplementation before any drug trial.
• Tier 2 (IRLS 11-20, adequate iron): Dopamine agonist at lowest effective dose, or gabapentin enacarbil 600 mg if OSA, insomnia, or neuropathic pain is present.
• Tier 3 (IRLS >20, or augmentation): Switch to or add pregabalin 150-300 mg nightly; arrange sleep specialist consultation; arrange IV iron if ferritin <100 mcg/L.
• Tier 4 (refractory, IRLS >20 on two adequate drug trials): Low-potency opioid with monitoring protocol; consider clinical trial enrollment.

Lifestyle and Non-Pharmacological Measures

Non-drug strategies rarely eliminate moderate-to-severe RLS on their own but are meaningful adjuncts. A systematic review of 14 trials found that aerobic exercise (three to four sessions per week, 30-60 minutes each) reduced IRLS scores by a mean of 5.1 points compared with sedentary controls [19]. Pneumatic compression devices applied for 60 minutes before bed reduced IRLS scores by 7.0 points in a randomized crossover trial (N=35) [20].

Caffeine restriction, avoidance of alcohol near bedtime, and a consistent sleep schedule all reduce symptom severity based on patient survey data, though controlled trial evidence is limited. Near-infrared light therapy and transcranial magnetic stimulation are investigational and not currently recommended outside research settings.